A new trading day began on Tuesday, with Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) stock price down -3.43% from the previous day of trading, before settling in for the closing price of $0.72. ADAP’s price has ranged from $0.43 to $2.05 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 134.88% over the last five years. Meanwhile, its annual earnings per share averaged 70.37%. With a float of $226.47 million, this company’s outstanding shares have now reached $255.70 million.
The firm has a total of 449 workers. Let’s measure their productivity. In terms of profitability, gross margin is 95.26%, operating margin of -28.14%, and the pretax margin is -28.42%.
Adaptimmune Therapeutics Plc ADR (ADAP) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Adaptimmune Therapeutics Plc ADR is 11.49%, while institutional ownership is 47.94%. The most recent insider transaction that took place on Jun 18 ’24, was worth 22,814. In this transaction Chief Commercial Officer of this company sold 24,531 shares at a rate of $0.93, taking the stock ownership to the 38,293 shares. Before that another transaction happened on Jan 17 ’24, when Company’s Chief Executive Officer sold 30,080 for $0.67, making the entire transaction worth $20,244. This insider now owns 44,848 shares in total.
Adaptimmune Therapeutics Plc ADR (ADAP) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 70.37% per share during the next fiscal year.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
Here are Adaptimmune Therapeutics Plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.21, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.08 in one year’s time.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Analysing the last 5-days average volume posted by the [Adaptimmune Therapeutics Plc ADR, ADAP], we can find that recorded value of 1.55 million was lower than the volume posted last year of 1.72 million. As of the previous 9 days, the stock’s Stochastic %D was 83.08%. Additionally, its Average True Range was 0.06.
During the past 100 days, Adaptimmune Therapeutics Plc ADR’s (ADAP) raw stochastic average was set at 14.02%, which indicates a significant decrease from 48.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 132.92% in the past 14 days, which was higher than the 81.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7969, while its 200-day Moving Average is $1.0970. Now, the first resistance to watch is $0.7256. This is followed by the second major resistance level at $0.7528. The third major resistance level sits at $0.7756. If the price goes on to break the first support level at $0.6756, it is likely to go to the next support level at $0.6528. Should the price break the second support level, the third support level stands at $0.6256.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Key Stats
With a market capitalization of 178.71 million, the company has a total of 255,883K Shares Outstanding. Currently, annual sales are 60,280 K while annual income is -113,870 K. The company’s previous quarter sales were 40,900 K while its latest quarter income was -17,620 K.
